Christine Lu
Neurology · San Leandro
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Hospitals listed: Kaiser Foundation Hospital - San Leandro. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Christine Lu’s office at (510) 454-1000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A157927 · Current
Licensed to practise in California · since 2018 · expires 2028-08-31 · University of Virginia School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Kaiser Foundation Hospital - San LeandroSan Leandro, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Kaiser Permanente, which runs 41 hospitals in 3 statesPatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.316, Oct 2024 – Sep 2025
See every measure and the patient survey for Kaiser Foundation Hospital - San Leandro
Behind the star rating — Deaths: 0 better, 1 the same, 0 worse of 1 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 1 the same, 1 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.316 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0 to 2.11) · 166 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.45 to 1.37) | No different | Jul 2022 – Jun 2024 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 190 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.3 · 2,150 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.44) · 728 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 762 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.32 (0.75 to 5.9) · 106 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 26 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.61 (0.89 to 4.33) · 97 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.83 (0 to 18.72) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.11 (0.82 to 9.4) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.09 (0.57 to 3.62) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.51) · 585 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.7 · 104 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.37 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.33 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.517 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 501 cases | None | Jul 2023 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.1 · 415 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 102 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.5 · 137 cases | None | Jul 2023 – Jun 2025 |
What patients said (635 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$1,314
Medicare paid this office $1,314 for 14 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
14 Original Medicare patients in 2024. Average age 63 · Health risk score 1.19. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75%.
The office billed $4,386, Medicare allowed $1,827 and paid $1,314; for 14 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 14 | 14 | 63 | 1.19 | $4,386 | $1,314 |
| 2022 | 13 | 14 | 68 | 1.94 | $3,399 | $1,266 |
| 2021 | 23 | 31 | 69 | 2.66 | $6,607 | $2,181 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
Drugs they prescribed that Part D paid
$497,095
Pharmacies billed $497,095 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
618 generic and fewer than 11 brand-name prescriptions · $497,095 in drug cost · 18 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Radicava Ors | 13 | $185,620 | $14,278 |
| Avonex Pen (4 Pack) | 13 | $104,315 | $8,024 |
| Avonex (4 Pack) | 12 | $95,965 | $7,997 |
| Rasagiline Mesylate | 30 | $3,789 | $126 |
| Mycophenolate Mofetil | 23 | $3,146 | $137 |
See all 19 drugs
| Radicava Ors | 13 | $185,620 | $14,278 |
| Avonex Pen (4 Pack) | 13 | $104,315 | $8,024 |
| Avonex (4 Pack) | 12 | $95,965 | $7,997 |
| Rasagiline Mesylate | 30 | $3,789 | $126 |
| Mycophenolate Mofetil | 23 | $3,146 | $137 |
| Carbidopa-Levodopa | 51 | $3,039 | $60 |
| Levetiracetam | 60 | $2,334 | $39 |
| Pyridostigmine | 24 | $1,485 | $62 |
| Quetiapine | 21 | $1,225 | $58 |
| Lamotrigine | 31 | $915 | $30 |
| Lacosamide | 18 | $831 | $46 |
| Riluzole | 22 | $734 | $33 |
| Tizanidine | 21 | $550 | $26 |
| Donepezil | 30 | $420 | $14 |
| Gabapentin | 18 | $391 | $22 |
| Topiramate | 14 | $192 | $14 |
| Clonazepam | 21 | $157 | $7 |
| Atorvastatin | 13 | $152 | $12 |
| Metoclopramide | 11 | $135 | $12 |
Year by year
| 2024 | 704 | 170 | None | None | $497,095 |
| 2023 | 793 | 174 | None | None | $639,847 |
| 2022 | 518 | 141 | None | None | $81,313 |
| 2021 | 292 | 107 | 0% (0) | None | $29,804 |
| 2020 | 81 | 39 | 0% (0) | None | $12,279 |
| 2019 | 182 | 32 | 0% (0) | 12% | $83,355 |
| 2018 | 124 | 26 | 0% (0) | None | $11,695 |
| 2017 | 108 | 20 | 0% (0) | 13% | $3,919 |
| 2016 | 69 | 27 | 0% (0) | None | $1,930 |
| 2015 | 23 | 15 | 0% (0) | None | $985 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Radicava Ors | 23 | $302,071 | $13,134 |
| Nurtec Odt | 17 | $15,233 | $896 |
| Rasagiline Mesylate | 31 | $4,707 | $152 |
| Carbidopa-Levodopa | 59 | $4,115 | $70 |
| Levetiracetam | 82 | $3,112 | $38 |
| Mycophenolate Mofetil | 17 | $2,813 | $165 |
| Pyridostigmine | 17 | $1,746 | $103 |
| Lacosamide | 28 | $1,304 | $47 |
| Entacapone | 13 | $1,134 | $87 |
| Lamotrigine | 33 | $1,069 | $32 |
| Gabapentin | 31 | $904 | $29 |
| Tizanidine | 18 | $489 | $27 |
| Primidone | 14 | $483 | $34 |
| Donepezil | 31 | $465 | $15 |
| Prednisone | 15 | $368 | $25 |
| Clonazepam | 43 | $322 | $7 |
| Topiramate | 11 | $264 | $24 |
| Baclofen | 11 | $205 | $19 |
| Pregabalin | 12 | $180 | $15 |
2022: 12 drugs
| Rasagiline Mesylate | 26 | $10,388 | $400 |
| Carbidopa-Levodopa | 67 | $4,499 | $67 |
| Pyridostigmine | 17 | $2,313 | $136 |
| Levetiracetam | 41 | $1,628 | $40 |
| Amantadine | 17 | $1,141 | $67 |
| Gabapentin | 21 | $653 | $31 |
| Baclofen | 15 | $429 | $29 |
| Donepezil | 20 | $336 | $17 |
| Clonazepam | 39 | $315 | $8 |
| Duloxetine | 14 | $309 | $22 |
| Prednisone | 13 | $307 | $24 |
| Lamotrigine | 11 | $267 | $24 |
2021: 8 drugs
| Levetiracetam | 30 | $1,826 | $61 |
| Carbidopa-Levodopa | 27 | $1,594 | $59 |
| Gabapentin | 19 | $410 | $22 |
| Tizanidine | 13 | $338 | $26 |
| Topiramate | 15 | $242 | $16 |
| Donepezil | 12 | $174 | $15 |
| Clonazepam | 20 | $172 | $9 |
| Atorvastatin | 11 | $172 | $16 |
2019: 4 drugs
| Glatiramer Acetate | 12 | $57,838 | $4,820 |
| Levetiracetam | 19 | $1,028 | $54 |
| Gabapentin | 23 | $111 | $5 |
| Topiramate | 11 | $90 | $8 |
2018: 3 drugs
| Gabapentin | 22 | $70 | $3 |
| Donepezil | 12 | $61 | $5 |
| Naproxen | 15 | $27 | $2 |
2017: 3 drugs
| Levetiracetam | 12 | $234 | $19 |
| Atorvastatin | 11 | $73 | $7 |
| Gabapentin | 20 | $66 | $3 |
Professional record
- NPI
- 1881080786
- Licence
- CA A157927California A157927: Current · expires 2028-08-31
- Trained
- University of Virginia School of Medicine, 2015
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084N0008X (2084N0008X); Student in a training program (390200000X)
- Mailing address
- 108 Moffett Blvd # C230, Mountain View, CA, 94043
- NPI first listed
- 2015-04-08
- NPI last updated
- 2021-12-17
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 353 E 17th St Fl 2, New York, NY, 10003
This office lists an electronic records connection.